Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg, Germany.
Am J Hum Genet. 2010 Feb 12;86(2):279-84. doi: 10.1016/j.ajhg.2010.01.013. Epub 2010 Feb 4.
Rhabdoid tumors of early infancy are highly aggressive with consequent poor prognosis. Most cases show inactivation of the SMARCB1 (also known as INI1 and hSNF5) tumor suppressor, a core member of the ATP-dependent SWI/SNF chromatin-remodeling complex. Familial cases, described as rhabdoid tumor predisposition syndrome (RTPS), have been linked to heterozygous SMARCB1 germline mutations. We identified inactivation of another member of the SWI/SNF chromatin-remodeling complex, its ATPase subunit SMARCA4 (also known as BRG1), due to a SMARCA4/BRG1 germline mutation and loss of heterozygosity by uniparental disomy in the tumor cells of two sisters with rhabdoid tumors lacking SMARCB1 mutations. SMARCA4 is thus a second member of the SWI/SNF complex involved in cancer predisposition. Its general involvement in other tumor entities remains to be established.
早发性婴儿横纹肌瘤侵袭性强,预后不良。大多数病例表现为 SMARCB1(也称为 INI1 和 hSNF5)肿瘤抑制因子失活,SMARCB1 是 ATP 依赖性 SWI/SNF 染色质重塑复合物的核心成员。家族性病例被描述为横纹肌瘤易感性综合征(RTPS),与 SMARCB1 种系突变杂合子有关。我们发现由于肿瘤细胞中 SMARCA4/BRG1 种系突变和单亲二体性导致的杂合性丢失,另一个 SWI/SNF 染色质重塑复合物的成员,其 ATP 酶亚基 SMARCA4(也称为 BRG1)失活,两个患有横纹肌瘤的姐妹的肿瘤缺乏 SMARCB1 突变。因此,SMARCA4 是 SWI/SNF 复合物的第二个易患癌症的成员。其在其他肿瘤实体中的普遍参与仍有待确定。